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Data sharing has incredible potential to strengthen academic research, the practice of medicine, and the integrity of the clini-
cal trial system. Some benefits are obvious: when 
researchers have access to com-
plete data, they can answer new 
questions, explore different lines 
of analysis, and more efficiently 
conduct large-scale analyses across 
trials. Other advantages, such as 
providing a guardrail against 
conflicts of interest in a clinical 
trial system in which external 
sponsorship of research is com-
mon and necessary, are less visi-
ble yet just as critical.
I appreciate that there are many 
policy, privacy, and practical is-
sues that need to be addressed in 
order to make data sharing prac-
tical and useful for the research 
community, but the stakes are 
too high to step back in the face 
of that challenge.
One policy proposal that I am 
particularly enthusiastic about is 
making data sharing a condition 
of publication in major medical 
journals. In a recent letter to the 
International Committee of Med-
ical Journal Editors (ICMJE), I ap-
plauded the committee’s work in 
developing a framework for data 
sharing.1 The ICMJE’s proposal 
would require that, as a condition 
of having their research manu-
scripts considered for publication, 
authors share the deidentified 
patient data on which their results 
are based. This requirement would 
be a significant step forward in 
improving the transparency of 
clinical trials for consumers and 
the academic medical community. 
Although the privacy of partici-
pants must be protected, access 
to the data underlying trial results 
can provide an avenue for inde-
pendent confirmation of results 
and further analyses of the data 
set, raising the bar for academic 
rigor and integrity and speeding 
the progress of medical research.
As I told the members of the 
ICMJE, I believe that linking data 
sharing with publication can also 
help address the patchwork land-
scape of current regulations relat-
ed to the sharing of clinical trial 
data. Because regulatory agencies 
have different protocols and re-
quirements for sharing data relat-
ed to the drugs and devices they 
approve, access to data about a 
clinical trial often hinges on which 
agency handles a regulatory sub-
mission rather than on the value 
of these data to consumers and 
researchers. By requiring data 
sharing as a condition of publica-
tion, journals can help synchro-
nize and expand existing data-
sharing practices.
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I am also encouraged by the 
potential of such proposals to 
improve compliance with exist-
ing laws and regulations related 
to the reporting of clinical trial 
results. Each of the several ongo-
ing efforts to increase data sharing 
through other routes has faced 
unique challenges. U.S. law has 
required the posting of summary 
clinical trial research results to 
the ClinicalTrials.gov database 
since the adoption of the Food 
and Drug Administration Amend-
ment Act (FDAAA) in 2007. How-
ever, recent analyses have high-
lighted variation across sectors 
when it comes to trial sponsors’ 
compliance with this law, in part 
due to a lack of final regulations, 
which leaves uncertainty about 
standards and impedes the ability 
of federal agencies to enforce re-
quirements.2-4 The European Med-
icines Agency has developed a 
policy that would require patient-
level data to be disclosed after a 
drug has been approved. This 
plan has been delayed because of 
disagreement among stakehold-
ers about how to share these 
data. Compliance with the more 
rigorous ICMJE requirements, 
though it will not automatically 
harmonize existing regulations, 
could nonetheless create a base-
line expectation that data will be 
shared and prepare researchers 
to comply with other mandates.
Requiring researchers to file a 
data-sharing plan for patient-level 
data when they initially register a 
trial could increase pressure on 
trial sponsors to post results in a 
timely fashion, regardless of the 
type of trial, the country of ori-
gin of the research, and whether 
or not the research is being per-
formed to support approval of a 
new medical product.
The costs associated with pre-
paring data for sharing can and 
should be built into the grants, 
cooperative agreements, and con-
tracts that researchers negotiate 
with trial sponsors; in other 
words, expenses associated with 
administering data-sharing pro-
tocols must be treated as a stan-
dard, necessary aspect of the 
costs of carrying out a clinical 
trial. And over the long run, data 
sharing may help reduce costs 
by allowing researchers to avoid 
duplicating trials or to answer 
questions without undertaking a 
separate data-collection effort.
Widespread practices of data 
sharing can also help to address 
concerns about conflicts of inter-
est that may arise when clinical 
trials are funded by industry 
sponsors that stand to profit 
from favorable research results. 
By making trial results available 
for independent scrutiny by out-
side reviewers, data sharing makes 
it less likely that trial sponsors 
can buy the analysis and results 
they want. Expanding opportu-
nities for scrutiny through data 
transparency raises the bar for 
integrity in analysis and interpre-
tation of results, helping to im-
prove the reproducibility and rigor 
of our clinical trial system.
As the research community 
and policymakers develop and 
implement data-sharing require-
ments, I urge them to craft clear 
standards for granting qualified 
researchers access to the data 
underlying published results in 
cases in which the data cannot 
be made public. I recognize that 
some types of data may necessi-
tate additional protections to pre-
serve the rights and privacy of 
trial participants and researchers. 
However, these protections should 
not place undue burdens on re-
searchers or restrict data access 
to an overly narrow pool of re-
searchers, nor should they be 
used to shield data from public 
view when no legitimate justifi-
cation exists for restricting pub-
lic access.
I understand the trepidation 
that some academics in medical 
research feel when they contem-
plate publicly sharing data. As an 
academic myself, I know the pro-
fessional stakes attached to credit 
for original research. I expect 
that the field will engage in vigo-
rous debate over what length of 
delay is appropriate before indi-
vidual-level patient data are re-
leased publicly. However, I urge 
researchers with concerns about 
academic credit or a new way of 
doing things not to lose sight 
of the bigger picture: transpar-
ency and reanalysis of data are 
core practices of rigorous, peer-
reviewed research, and increas-
ing access to data will ultimately 
strengthen — rather than erode 
— these practices.
Finally, in considering how to 
encourage data sharing, I urge 
members of the medical research 
community to also consider ways 
to improve the public sharing of 
information from trials that have 
produced null, inconclusive, or 
negative results. As a recent study 
emphasized, negative trial results 
have a “sizeable scientific im-
pact,” yet they are less likely to 
find their way into the pages of 
major medical journals.5 Encour-
aging the publication of such 
trials and the release of their 
underlying data will help to fur-
ther accelerate medical progress, 
uphold the ethical standards of 
human-subjects research, and help 
in holding industry sponsors ac-
countable.
Data sharing holds incredible 
promise for strengthening the 
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practice of medical research and 
the integrity of our clinical trial 
system. I look forward to follow-
ing these proposals as they con-
tinue to develop and urging their 
implementation.
Disclosure forms provided by the author 
are available at NEJM.org.
Elizabeth Warren (D-MA) is a U.S. senator.
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A clinician researcher has an idea for a study that could 
change practice. The researcher 
identifies an existing data set 
that is ideal for her study — other 
researchers conducted a clinical 
trial, produced this data set, and 
published a report of the primary 
findings. Time has passed since 
the initial publication, and the 
data are not being used. But this 
clinical investigator may not be 
able to pursue her question, since 
data from clinical trials are often 
not shared, and researchers may 
be discouraged from working 
with clinical trial data they did 
not generate themselves.
The experience of clinical re-
searchers differs markedly from 
that of many physicists, astrono-
mers, and geneticists, who active-
ly share data from resources such 
as the Large Hadron Collider, the 
Hubble Space Telescope, and the 
Human Genome Project. Various 
leaders and organizations are now 
pushing for medical research to 
change in this regard. Vice Presi-
dent Joe Biden has made data 
sharing an essential feature of 
the cancer “moonshot.” Private- 
and public-sector research funders 
are developing clear expectations 
for sharing data from the work 
they support. For example, in 
2015 the National Institutes of 
Health made explicit its intent to 
make public the digital data from 
its funded studies. The pharma-
ceutical industry has articulated 
principles that support data shar-
ing, and many companies have 
implemented programs to make 
their data assets available. Regu-
latory agencies, most notably the 
European Medicines Agency, are 
requiring greater sharing by com-
panies seeking to market drugs 
and devices, and influential or-
ganizations such as the World 
Health Organization and the Na-
tional Academy of Medicine have 
released reports calling for re-
sponsible sharing of clinical trial 
data.1 Notably, the policy of the 
Bill and Melinda Gates Founda-
tion is that the data underlying 
published results be made avail-
able and open immediately.
Amid this activity, the Inter-
national Committee of Medical 
Journal Editors (ICMJE) stepped 
forward with a proposal to accel-
erate the transformation to a cul-
ture of open science.2 The ICMJE 
asserted its belief that data own-
ers have “an ethical obligation to 
responsibly share data generated 
by interventional clinical trials.” 
The committee proposed requir-
ing authors to make deidentified 
individual-participant data under-
lying the results in a published 
report from a clinical trial avail-
able for sharing no more than 
6 months after publication — a 
slightly more permissive policy 
than that of the Gates Founda-
tion. It has also proposed that 
authors prospectively include a 
plan for data sharing as part of 
the registration of clinical trials. 
The ICMJE proposal has the po-
tential to spur the transforma-
tion of the research culture so 
that data sharing becomes the 
norm. Indeed, if properly imple-
mented, the proposal could pro-
mote a culture that maximizes 
the contributions of patients who 
volunteer to participate in clini-
cal trials.
This proposal is not the first 
time that the ICMJE has used its 
influence to improve the clinical 
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